ADMA Live signals | Maximize Profits with Getagraph.com

SELL 94250 min ago

@ $5.32

Issued: 14 Feb 2024 @ 15:41

Return: 17.97%

Previous signal: Feb 14 - 13:10

Previous signal: Buy

Return: 0.90 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	3.18M
Average Volume	2.58M
Market Cap	1.45B
EPS	$0 ( 2024-02-28 )
Next earnings date	( $0.0500 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-48.23
ATR14	$0.00900 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Kestenberg-messina Kaitlin M.	Buy	192 320	Common Stock
2024-04-01	Kestenberg-messina Kaitlin M.	Buy	300 328	Stock Option (right to buy)
2024-03-31	Kestenberg-messina Kaitlin M.	Sell	2 085	Common Stock
2024-03-31	Grossman Adam S	Sell	21 752	Common Stock
2024-04-01	Kestenberg-messina Kaitlin M.	Sell	0	Common Stock

INSIDER POWER
-15.51
Last 100 transactions
Buy: 7 559 578 \| Sell: 9 852 560

Volume Correlation

Long: 0.22 (neutral)

Short: 0.67 (moderate)

Signal:(73.787) Neutral

ADMA Biologics Inc Correlation

10 Most Positive Correlations
LWAC	0.924
PRTA	0.912
CAC	0.91
ZGNX	0.906
ADMS	0.903
CRSP	0.901
NERV	0.897
GNLN	0.894
VYNE	0.894
JFU	0.893

10 Most Negative Correlations
GOODM	-0.901
SVAC	-0.878
THMA	-0.874
DTEA	-0.869
TLGT	-0.868
SBBP	-0.863
PETV	-0.861
RMRM	-0.86
NAII	-0.851
NRDS	-0.851

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ADMA Biologics Inc Correlation - Currency/Commodity

-0.40
( neutral )

-0.48
( neutral )

0.00
( neutral )

0.75
( moderate )

-0.72
( moderate negative )

ADMA Biologics Inc Financials

Annual	2023
Revenue:	$258.21M
Gross Profit:	$88.22M (34.16 %)
EPS:	$-0.130

Q4	2023
Revenue:	$73.90M
Gross Profit:	$30.90M (41.81 %)
EPS:	$-0.0781

Q3	2023
Revenue:	$67.27M
Gross Profit:	$24.65M (36.64 %)
EPS:	$0.0114

Q2	2023
Revenue:	$60.12M
Gross Profit:	$16.69M (27.76 %)
EPS:	$-0.0286

Financial Reports:

No articles found.

ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.